This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| pancreatic cancer | |
|---|---|
| Name | Pancreatic cancer |
| Field | Oncology, Gastroenterology, Pathology |
| Symptoms | Jaundice, abdominal pain, weight loss, anorexia |
| Complications | Metastasis, cachexia, biliary obstruction |
| Onset | Typically older adults |
| Duration | Variable |
| Types | Adenocarcinoma, neuroendocrine tumor |
| Causes | Smoking, chronic pancreatitis, germline mutations |
| Risks | Age, family history, diabetes |
| Diagnosis | Imaging, biopsy, tumor markers |
| Treatment | Surgery, chemotherapy, radiotherapy, targeted therapy |
pancreatic cancer is a malignant neoplasm arising from the pancreas, most commonly from the pancreatic ductal epithelium. It is notable for late presentation, aggressive local invasion, early metastatic spread, and poor overall survival. Management integrates surgical oncology, medical oncology, and interventional radiology, with ongoing research in molecular targeted therapy and immunotherapy.
Presentation often reflects local invasion and systemic effects. Patients may report progressive jaundice-associated scleral icterus, steatorrhea, and unintentional weight loss; these findings may prompt evaluation by clinicians from Mayo Clinic, Johns Hopkins Hospital, or regional academic centers such as Massachusetts General Hospital. Abdominal or back pain radiating to the back, new-onset diabetes evaluated by endocrinologists at institutions like Cleveland Clinic or Mount Sinai Health System, and nonspecific constitutional symptoms commonly lead to referral to surgical teams at centers like Memorial Sloan Kettering Cancer Center or MD Anderson Cancer Center. Painless obstructive jaundice can result in referral to hepatobiliary units in tertiary centers such as Addenbrooke's Hospital or Royal Marsden Hospital.
Major environmental and hereditary contributors include tobacco exposure identified in cohort studies from World Health Organization collaborators, chronic pancreatitis as described in registries at European Pancreatic Club, and obesity trends tracked by Centers for Disease Control and Prevention. Germline mutations in genes such as BRCA1 and BRCA2 inform genetic counseling pathways at institutions like Genetic Counseling Service (UK) and Invitae. Occupational exposures evaluated by investigators at National Institute for Occupational Safety and Health and alcohol-related chronic pancreatitis noted in case series from Karolinska Institute are implicated. Increasing age and family clustering prompt surveillance programs at specialty centers including Johns Hopkins Hospital and University of California, San Francisco.
Most tumors are pancreatic ductal adenocarcinomas arising from ductal epithelium through precursor lesions such as pancreatic intraepithelial neoplasia characterized in pathology reports from College of American Pathologists archives. Molecular alterations commonly involve KRAS, TP53, CDKN2A, and SMAD4 described in genomic studies from The Cancer Genome Atlas and sequenced in cohorts at Broad Institute. Less common neoplasms include pancreatic neuroendocrine tumors with distinctions clarified by consensus guidelines from World Health Organization and clinical series at European Neuroendocrine Tumor Society. Histopathologic grading and immunohistochemistry are standardized by protocols from International Agency for Research on Cancer and practiced in diagnostic laboratories at laboratories accredited by College of American Pathologists.
Diagnostic evaluation combines cross-sectional imaging, endoscopic assessment, laboratory markers, and tissue sampling. Contrast-enhanced computed tomography performed in radiology departments at Royal College of Radiologists-affiliated hospitals and magnetic resonance imaging interpreted by neuroradiology/radiology teams such as those at Sir Charles Gairdner Hospital identify mass lesions and vascular involvement. Endoscopic ultrasound with fine-needle aspiration is performed by gastroenterology services like those at European Society of Gastrointestinal Endoscopy member centers. Serum CA 19-9 measurement used in clinical practice at institutions including Mayo Clinic provides adjunctive information. Multidisciplinary tumor boards at comprehensive cancer centers such as MD Anderson Cancer Center integrate pathology from College of American Pathologists and imaging to reach a diagnosis.
Staging employs the tumor-node-metastasis (TNM) system promulgated by the American Joint Committee on Cancer and harmonized with guidelines from Union for International Cancer Control. Stage determination uses imaging from centers like Royal Marsden Hospital and laparoscopic assessment in operative units at Johns Hopkins Hospital to evaluate resectability, vascular encasement, and distant spread to liver, peritoneum, and lungs. Radiologic staging influences categorization into resectable, borderline resectable, locally advanced unresectable, and metastatic disease as per consensus statements from International Association of Pancreatology.
Curative-intent therapy centers on surgical resection (pancreaticoduodenectomy, distal pancreatectomy) performed at high-volume centers such as Memorial Sloan Kettering Cancer Center and Mayo Clinic often followed by adjuvant chemotherapy regimens studied in trials led by European Organisation for Research and Treatment of Cancer and National Cancer Institute. Neoadjuvant strategies and systemic chemotherapy utilize combinations like FOLFIRINOX and gemcitabine-based regimens evaluated by cooperative groups including North American Association of Central Cancer Registries and EORTC. Radiotherapy techniques from departments such as MD Anderson Cancer Center and stereotactic body radiotherapy centers are used selectively. Targeted therapies and PARP inhibitors informed by BRCA status are implemented following evidence from trials supported by American Society of Clinical Oncology and genetic services like Invitae. Palliative care teams affiliated with Hospice UK and symptom-directed interventions by interventional radiology (e.g., biliary stenting) at tertiary hospitals ameliorate complications.
Overall prognosis remains poor, with 5-year survival historically in the single digits but improving modestly in specialized cohorts treated at referral centers like Johns Hopkins Hospital and MD Anderson Cancer Center. Prognosis varies by stage: resectable disease treated surgically at high-volume centers yields higher survival reported in series from Memorial Sloan Kettering Cancer Center, whereas metastatic disease managed in oncology units at Royal Marsden Hospital has markedly lower median survival. Tumor biology (KRAS, TP53 status) and patient factors influence outcomes described in analyses by The Cancer Genome Atlas and population data from Surveillance, Epidemiology, and End Results Program.